Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 2012 Oct; 3(10):1194-203.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.